Betahistine-d3 (dihydrochloride)

Betahistine-d3 (dihydrochloride) is the deuterium labeled Betahistine dihydrochloride. Betahistine dihydrochloride is an orally active histamine H1 receptor agonist and a H3 receptor antagonist[1]. Betahistine dihydrochloride is used for the study of rheumatoid arthritis (RA) [3].

Product Specifications

CAS Number

[244094-72-2]

UNSPSC

12352005

Hazard Statement

H315-H319-H335

Target

Histamine Receptor

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Field of Research

Endocrinology; Inflammation/Immunology; Neurological Disease

Purity

99.0

Solubility

10 mM in DMSO|DMF : 5mg/mL (ultrasonic) |DMSO : 33.33mg/mL (ultrasonic) |H2O : ≥ 50mg/mL

Smiles

[2H]C([2H])([2H])NCCC1=CC=CC=N1.Cl.Cl

Molecular Formula

C8H11D3Cl2N2

Molecular Weight

212.13

Precautions

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Poyurovsky M, et al. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005 Mar;20 (2) :101-3.|[3]Gbahou F, et al. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.J Pharmacol Exp Ther. 2010 Sep 1;334 (3) :945-54.|[4]Tang KT, et al. Betahistine attenuates murine collagen-induced arthritis by suppressing both inflammatory and Th17 cell responses.Int Immunopharmacol. 2016 Oct;39:236-245.